Agenus Reported Survival Data for Ovarian Cancer Trial
The study assessed the combination of botensilimab and balstilimab in patients with recurrent ovarian cancer.
Updated on Oct. 3, 2026 in Cancer
Live Poll
Do you trust that new experimental immunotherapy treatments will lead to better long-term survival outcomes?
Agenus announced three-year survival results from a clinical trial involving 44 patients with recurrent ovarian cancer. The combination therapy achieved a 48% overall survival estimate at the three-year mark.
Why it matters
This study addressed a critical need for patients with recurrent ovarian cancer who have exhausted all standard therapeutic options. The findings provide insight into the efficacy of combining botensilimab and balstilimab in difficult-to-treat cases.
The clinical trial reported a 14.8-month median overall survival and a 23% objective response rate among 44 participants. Additionally, 25% of patients who received at least one treatment dose remained alive and off all therapy.
The players
Agenus
This is a biotechnology company based in Lexington, Massachusetts, that focuses on developing immune-oncology therapies.
International Gynecologic Cancer Society
This professional organization hosted its annual global meeting in Montréal to disseminate research on gynecologic cancers.
The details
The trial focused on patients with recurrent ovarian cancer, nearly three-quarters of whom had platinum-resistant or refractory disease. No new safety signals or treatment-related deaths were observed during the study period.
Timeline
December 13, 2025: Data cutoff for the clinical analysis.
October 3, 2026: Results presented at the International Gynecologic Cancer Society Annual Global Meeting.
The Big Picture
This study follows the precedent of ongoing research presented at the International Gynecologic Cancer Society Annual Global Meeting. It highlights how clinical trials are increasingly targeting late-stage ovarian cancer populations with no remaining standard therapy.
The trial results offer potential hope for patients who have already undergone multiple rounds of unsuccessful therapy. Future clinical developments may allow this treatment combination to be utilized earlier in the disease progression.
The takeaway
The data confirms that a subset of patients with recurrent ovarian cancer can achieve stable disease or response for over 24 weeks. Moving treatment to earlier stages remains a primary goal for future study iterations.
Further reading
For more information on current treatment pathways, visit our dedicated Cancer section.
More information
View detailed study information at the Agenus publications and presentation portal.
Live Poll
Do you trust that new experimental immunotherapy treatments will lead to better long-term survival outcomes?
